Evergreen Talk Series: Linagliptin and Dapagliflozin combination for T2DM with Cardiovascular risk or established ASCVD MD Brand Connect21 Dec 2023 11:45 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr. Sameer I. Dani,...
Dapagliflozin may improve symptoms in patients with HFrEF with limited impact on exercise capacity Dr. Shravani Dali19 Dec 2023 7:45 PM ISTDapagliflozin may improve symptoms in patients with HFrEF with limited impact on exercise capacity suggests a new study published in the...
Linagliptin and Dapagliflozin: Therapeutic Applicability in T2DM with High CV Risk Dr. Kamal Kant Kohli13 Dec 2023 11:48 AM ISTType 2 Diabetes Mellitus and Cardiovascular DiseaseType 2 diabetes mellitus (T2DM) prevalence has been increasing globally, particularly in India (1)...
5mg Dapagliflozin every day attenuates CV events among diabetes patients with chronic HF Dr. Kamal Kant Kohli5 Dec 2023 11:15 AM ISTThe DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18...
First Indian Evidence: Triple FDC (DAPA, SITA, MET ER) Yields Better HbA1c Reduction in T2DM Patients Uncontrolled on Existing Therapy Dr. Kamal Kant Kohli2 Dec 2023 11:43 AM ISTAn approach of using a once-daily triple fixed-dose combination of dapagliflozin, sitagliptin, and metformin ER (extended-release) in Indian type 2...
Evergreen Talk Series: Clinical applicability of Linagliptin in T2DM across CKD spectrum and Dapagliflozin up to CKD stage 4 MD Brand Connect1 Dec 2023 11:17 AM IST Advertisement Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and...
Combination of ERA and SGLT2 inhibitor reduced albuminuria in patients with chronic kidney disease: ZENITH-CKD trial Medha Baranwal23 Nov 2023 9:30 AM ISTNetherlands: A combination of zibotentan and dapagliflozin reduced albuminuria with an acceptable safety and tolerability profile, according to phase...
Evergreen Talk Series: Clinical Benefits of Linagliptin and Dapagliflozin Combination in Type 2 Diabetes Management MD Brand Connect10 Nov 2023 11:54 AM IST Advertisement Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a...
Continuation of dapagliflozin beneficial among HF patients with deteriorating kidney function Dr.Niharika Harsha B8 Nov 2023 7:00 PM ISTIn a recent study, researchers have explored the safety and effectiveness of continuing treatment with sodium-glucose cotransporter-2 (SGLT2)...
Zibotentan plus dapagliflozin demonstrated significant albuminuria reduction in patients with chronic kidney disease, proteinuria: AstraZeneca Ruchika Sharma5 Nov 2023 1:00 PM ISTCambridge: AstraZeneca has announced that the combination of zibotentan with dapagliflozin has shown statistically significant and clinically...
Exemed Gets CDSCO Panel Nod To study dapagliflozin, Sacubitril, Valsartan as Sodium salt tablet Dr. Divya Colin29 Oct 2023 1:21 PM ISTNew Delhi: Exemed Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Abbott Gets CDSCO Panel Nod To Study Antidiabetic FDC Dapagliflozin plus Metformin Dr. Divya Colin21 Oct 2023 7:00 PM ISTNew Delhi: The drug major Abbott Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
